15231-48-8Relevant articles and documents
Redox deracemization of phosphonate-substituted dihydropyrimidines
Feng, Guang-Shou,Guo, Xuan,Meng, Fan-Jie,Shao, Bing-Ru,Shi, Lei,Velopolcek, Maria K.
supporting information, p. 10570 - 10574 (2021/12/27)
An efficient redox deracemization of the phosphonic ester substituted 3,4-dihydropyrimidin-2-one (DHPM) derivatives is described. The one-pot deracemization strategy consisted of the oxidization to destroy the stereocenter center and the following asymmetric transfer hydrogenation to regenerate the chiral carbon center with the vicinal phosphonic ester group, providing a series of optically active phosphonate substituted DHPMs with up to 96% ee.
PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
-
, (2010/03/02)
The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.
SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS
-
Page/Page column 75, (2008/06/13)
The invention relates to the substituted N-heterocyclic compounds of general formula (I), wherein Ar, A1, X, Y, A2 and Q are defined as in claim 1, and to the tautomers of the compounds (I), the physiologically acceptable salts of compounds (I) and the physiologically acceptable salts of the tautomers of compound (I). The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases that respond to the influence exerted by dopamine D3 receptor ligands, especially for treating diseases of the central nervous system, especially schizophrenia and/or depression.